PKM2 aggregation drives metabolism reprograming during aging process

Juntao Bie, Ridong Li, Yutong Li, Song Chen, Zhaoming Chen, Tianzhuo Zhang, Zhiheng Tang, Li Su, Liangyi Zhu, Jiaxin Wang, You Wan, Jun Chen, Xiaoyun Liu, Tingting Li, Jianyuan LuoNature Communications 2024 · DOI

TL;DR

This study reveals that the protein PKM2 forms aggregates in aging cells and tissues, impairing its function and driving cellular senescence. The researchers identified two compounds, K35 and K27, that can dissolve these aggregates, reverse aging markers, and extend lifespan in mice, suggesting a novel therapeutic target for aging.

What Problem Does This Paper Address?

Aging is a complex process characterized by the decline of cellular and tissue function, often leading to age-related diseases. While protein aggregation is a known hallmark of aging and diseases like Alzheimer's and Parkinson's, the specific proteins involved in general organismal aging and whether targeting these aggregates can alleviate aging remain unclear. This paper aims to fill this knowledge gap by investigating the role of protein aggregation in the aging process and exploring potential therapeutic interventions.

Methods

The researchers employed a multi-pronged approach:

  • Lysosomal Proteomics: They analyzed the protein content of lysosomes isolated from young and senescent cells to identify proteins that accumulate with age.
  • Mass Spectrometry (MS): Used to identify and quantify proteins within PKM2 aggregates.
  • Western Blotting and Immunofluorescence: Standard techniques to validate protein expression and localization.
  • Cellular Senescence Induction: Used etoposide, camptothecin, and 5-FU to induce senescence in various cell lines (HEK 293T, HeLa, MCF-7, 2BS). Replicative senescence was induced by passaging cells.
  • Small Molecule Library Screening: A two-step screening process was used to identify compounds that could dissolve PKM2 aggregates and alleviate senescence.
  • Enzyme Activity Assays: PKM2 enzymatic activity was measured using LDH-coupled assays and commercial kits.
  • Glycolytic Flux Measurement: Lactate production in cell culture media was quantified as an indicator of glycolytic flux.
  • In Vivo Studies:
    • Doxorubicin-induced aging model: Mice were treated with doxorubicin to accelerate aging, followed by administration of K35/K27.
  • Naturally aged mice model: Aged mice were treated with K35/K27.
  • Behavioral tests: Grip strength and rotarod tests were used to assess physical function.
  • Biochemical analyses: Blood and serum were analyzed for various markers.
  • Histology and Immunohistochemistry: Tissues were analyzed for senescence markers (SA-β-gal, p53, p21, p16) and PKM2 aggregation.
  • RNA Sequencing: Used to assess changes in gene expression related to aging and senescence.
  • Molecular Docking and Microscale Thermophoresis (MST): Used to investigate the binding interaction between K35/K27 and PKM2.

Datasets

Not explicitly discussed as training datasets. The study utilizes data generated from their own experiments on cell lines and mice models.

Key Insights and Ideas

  • PKM2 Aggregation as a Driver of Aging: The study provides strong evidence that PKM2 aggregation, not just its abundance, is a key factor in driving cellular senescence and aging phenotypes.
  • PKM2 Aggregates Impair Glycolysis: The formation of PKM2 aggregates disrupts its enzymatic activity and the glycolytic pathway, leading to cellular dysfunction.
  • Lysosomes and PKM2 Aggregates: Senescent cells show increased lysosomal content of glycolytic enzymes, including PKM2, suggesting a role for lysosomes in managing or accumulating these aggregates.
  • Targeting PKM2 Aggregates for Anti-Aging: The identification of K35 and K27 as effective PKM2 aggregate disrupters opens a new therapeutic avenue for combating aging.
  • In Vivo Efficacy: K35 and K27 demonstrate significant anti-aging effects in both prematurely and naturally aged mice, extending lifespan and improving physical function.

Key Results

  • PKM2 forms aggregates in senescent cells and organs of aged mice.
  • PKM2 aggregation impairs PKM2 enzymatic activity and glycolytic flux, contributing to cellular senescence.
  • A two-step screening identified K35 and K27 as compounds that dissolve PKM2 aggregates and alleviate senescence.
  • Treatment with K35 and K27 restored PKM2 enzymatic activity and glycolytic flux.
  • K35 and K27 significantly extended the lifespan of both prematurely aged (doxorubicin-induced) and naturally aged mice.
  • K35 and K27 improved physical function (grip strength, rotarod performance) in aged mice.
  • K35 and K27 reduced senescence markers (p53, p21, p16, SASP genes) in aged mice tissues.
  • Molecular docking and MST confirmed that K35 and K27 bind to PKM2, likely disrupting its aggregation.

Limitations and Future Work

  • Mechanism of PKM2 Aggregation: While the study identifies PKM2 aggregation as a driver of aging, the precise upstream triggers and detailed molecular mechanisms leading to its formation require further investigation.
  • PKM2 Aggregate Composition: While PKM2 aggregates were found to contain other glycolytic enzymes, a comprehensive understanding of all components and their roles within these aggregates is needed.
  • Crystal Structure of PKM2 Aggregates: The authors suggest that resolving the crystal structure of PKM2 aggregates and their co-crystals with K35/K27 would provide deeper insights into the dissolution mechanism and aid in optimizing these compounds.
  • High-Throughput Screening for Analogs: The authors propose using structure-based virtual screening to identify more potent PKM2 aggregate-dissolving compounds.
  • Long-term Toxicity of K35/K27: While initial toxicity tests in mice showed minimal adverse effects, long-term safety studies would be crucial for clinical translation.
  • Specific Organ Effects: While the study shows broad anti-aging effects, further research could focus on the specific impact of PKM2 aggregation and K35/K27 treatment on individual organs and tissues.

Summary updated

Abstract

While protein aggregation's association with aging and age-related diseases is well-established, the specific proteins involved and whether dissolving them could alleviate aging remain unclear. Our research addresses this gap by uncovering the role of PKM2 aggregates in aging. We find that PKM2 forms aggregates in senescent cells and organs from aged mice, impairing its enzymatic activity and glycolytic flux, thereby driving cells into senescence. Through a rigorous two-step small molecule library screening, we identify two compounds, K35 and its analog K27, capable of dissolving PKM2 aggregates and alleviating senescence. Further experiments show that treatment with K35 and K27 not only alleviate aging-associated signatures but also extend the lifespan of naturally and prematurely aged mice. These findings provide compelling evidence for the involvement of PKM2 aggregates in inducing cellular senescence and aging phenotypes, and suggest that targeting these aggregates could be a promising strategy for anti-aging drug discovery.
BibTeX
@inproceedings{bie2024pkm,
  author = {Juntao Bie and Ridong Li and Yutong Li and Song Chen and Zhaoming Chen and Tianzhuo Zhang and Zhiheng Tang and Li Su and Liangyi Zhu and Jiaxin Wang and You Wan and Jun Chen and Xiaoyun Liu and Tingting Li and Jianyuan Luo},
  title = {{PKM2 aggregation drives metabolism reprograming during aging process}},
  booktitle = {Nature Communications},
  year = {2024},
  doi = {10.1038/s41467-024-50242-y},
}
Figure